Physician profile
Olivia Aranha
NPI 1386841211
$12,433.82
in general payments reported to CMS, 2019-2025
13 companies · $599 in 2025
The $599 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2021: $19.42 · 2022: $113 · 2023: $11K · 2024: $274 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $1,051 · Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,150.00 |
| Travel and Lodging | $1,051.42 |
| Food and Beverage | $962.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $11,291.16 | 2023 | Tukysa |
| Astrazeneca Pharmaceuticals Lp | $370.07 | 2024-2025 | Imfinzi |
| Astrazeneca Uk Limited | $174.35 | 2025 | |
| Array Biopharma INC | $138.67 | 2024 | |
| Amgen INC. | $123.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $113.10 | 2022 | |
| Janssen Scientific Affairs, LLC | $103.84 | 2025 | Rybrevant |
| Beone Medicines USA, INC. | $64.55 | 2025 | Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $21.02 | 2025 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2021 | |
| Clovis Oncology, INC. | $14.40 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Aranha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.